Why It Matters

Exact Sciences needs to secure Medicare coverage for multi-cancer early detection tests before market conditions shift. The company’s challenge: current Medicare policy doesn’t cover the innovative blood-based screening tests it’s developing, limiting revenue to private insurance and out-of-pocket payments.

The legislative solution is the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 842 / S. 339), which would mandate Medicare coverage for FDA-approved MCED tests. The timing is exceptional: the bill has 332 House co-sponsors and 67 Senate co-sponsors, passed the House as part of a major appropriations package, and achieved unanimous committee passage in September 2025.

By the Numbers

Exact Sciences Corp. reported $420,000 in internal lobbying expenditures for the last quarter of 2025, continuing a two-decade government affairs presence. The company has filed 158 total disclosures since 2003, with cumulative spending exceeding $13 million.

This quarter’s effort is led by three dedicated lobbyists: Ashli Carpi Douglas ($8.66 million in Exact Sciences filings since 2019), Julia McNerney ($8.02 million since October 2021), and Jesse Shelburne ($4.69 million since July 2023).

The company maintains relationships with specialized external firms: Duberstein Group Inc. has earned $975,000 since 2022 on Medicare coverage initiatives, while Alpine Group Partners LLC received $1.14 million since 2021 focused on MCED coverage.

The Agenda

Exact Sciences is lobbying Congress to expand Medicare coverage for multi-cancer early detection blood tests, focusing on the Nancy Gardner Sewell Medicare MCED Screening Coverage Act. The legislation would require Medicare to cover FDA-approved multi-cancer screening tests, particularly blood-based liquid biopsies.

Beyond this flagship bill, the company advocates on related measures including the Reducing Hereditary Cancer Act, the Finn Sawyer Access to Cancer Testing Act, and the Colorectal Cancer Early Detection Act.

Broader Context

The legislative environment reflects powerful bipartisan support. Rep. Terri Sewell (D-AL-7) frequently invokes her mother’s pancreatic cancer death to underscore early detection urgency. Rep. Jodey Arrington (R-TX-19) highlighted Dallas Cowboys quarterback Dak Prescott’s advocacy helping an employee detect cancer early.

Clinical evidence strengthens the case. GRAIL’s PATHFINDER 2 study demonstrated that multi-cancer early detection tests increased cancer detection more than seven-fold when added to standard screening.

Abbott Laboratories’ $21 billion acquisition of Exact Sciences in November 2025 significantly amplifies the company’s regulatory influence through Abbott’s global distribution capabilities and $9.34 billion diagnostics portfolio.

Between The Lines

Congress is moving with unusual speed on cancer screening legislation. Leadership leans heavily on personal narratives—Sewell’s mother’s death, Prescott’s advocacy—to drive momentum for the MCED bill.

No substantive congressional hearings have directly addressed MCED technologies, suggesting policy discussions happen primarily through direct legislative advocacy rather than public forums.

Competitive Landscape

GRAIL Inc. has lobbied on MCED issues through Grant Park Strategies LLC with $30,000 quarterly expenses, advocating for the same Multi-Cancer Early Detection Screening Coverage Act. Geneoscopy Inc. engaged Venable LLP with $30,000 in Q4 2024 for colorectal cancer screening access. Rather than zero-sum competition, these companies have created a unified advocacy front, substantially increasing legislative success likelihood.

The Bottom Line

Exact Sciences’ fourth quarter lobbying push focuses almost entirely on securing Medicare coverage for multi-cancer early detection tests. The company’s efforts align with exceptional congressional momentum: the MCED bill has supermajority support and already passed the House. The legislation faces minimal opposition, reflecting broad bipartisan support driven by personal narratives and genuine public health need. Abbott’s pending acquisition substantially amplifies Exact Sciences’ policy influence, while competitor alignment creates unified industry pressure on Capitol Hill.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article